<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="47">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05160532</url>
  </required_header>
  <id_info>
    <org_study_id>21-008778</org_study_id>
    <nct_id>NCT05160532</nct_id>
  </id_info>
  <brief_title>Intraarticular Dextrose Prolotherapy for Symptomatic Knee Osteoarthritis</brief_title>
  <official_title>Intraarticular Dextrose Prolotherapy for Symptomatic Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to learn more about treating Symptomatic Knee Osteoarthritis&#xD;
      (OA) with an ultrasound-guided hypertonic dextrose injection. Researchers would like to&#xD;
      determine best practice for injection frequency and effectiveness of the dextrose injection&#xD;
      for symptomatic knee OA.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks, 16 weeks, 26 weeks, and 52 weeks</time_frame>
    <description>Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) disease-specific tool used to measure physical function, pain, and stiffness in individuals with knee OA. Total scores range from 0-100, with higher scores indicating worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in pain</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks, 16 weeks, 26 weeks, and 52 weeks</time_frame>
    <description>Measured using a visual analogue scale with 0 = no pain and 10=worst pain.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Four injections of placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive four placebo intraarticular knee injections under ultrasound guidance. A placebo looks exactly like the study drug, but it contains no active ingredient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>One injection of DPT and three injections of placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive one intraarticular knee injection under ultrasound guidance of dextrose prolotherapy (DPT), followed by three intraarticular knee injections of placebo under ultrasound guidance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Two injections of DPT and two injections of placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive two intraarticular knee injection under ultrasound guidance of dextrose prolotherapy (DPT), followed by two intraarticular knee injections of placebo under ultrasound guidance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Four injections of DPT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive four intraarticular knee injection under ultrasound guidance of dextrose prolotherapy (DPT).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>5ml of normal saline (NS)</description>
    <arm_group_label>Four injections of placebo</arm_group_label>
    <arm_group_label>One injection of DPT and three injections of placebo</arm_group_label>
    <arm_group_label>Two injections of DPT and two injections of placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextrose prolotherapy (DPT)</intervention_name>
    <description>25% dextrose, mixing 2.5ml of sterile water and 2.5ml of 50% dextrose.</description>
    <arm_group_label>Four injections of DPT</arm_group_label>
    <arm_group_label>One injection of DPT and three injections of placebo</arm_group_label>
    <arm_group_label>Two injections of DPT and two injections of placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of knee OA by clinical criteria (American College of Rheumatology).&#xD;
&#xD;
          -  Identification of knee osteoarthritis by a radiologist on an existing knee radiograph&#xD;
             obtained within 3 years of enrollment.&#xD;
&#xD;
          -  Moderate to severe knee pain for at least 3 months, defined as a score of â‰¥ 4 (on a&#xD;
             0-10 point numeric rating scale) in response to the question &quot;What is the average&#xD;
             level of your left/right knee pain in the past 3 months?&quot;.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Diabetes.&#xD;
&#xD;
          -  Anticoagulation therapy.&#xD;
&#xD;
          -  History of total knee replacement.&#xD;
&#xD;
          -  Prior knee prolotherapy or other regenerative product.&#xD;
&#xD;
          -  Any knee injection within 3 months.&#xD;
&#xD;
          -  Inflammatory (RA, gout, pseudogout etc.) or postinfectious knee arthritis.&#xD;
&#xD;
          -  Daily use of opioid medication.&#xD;
&#xD;
          -  Allergy or intolerance to study medication, corn allergy.&#xD;
&#xD;
          -  Body mass index (BMI) greater than 40 kg/m^2.&#xD;
&#xD;
          -  Comorbidity severe enough to prevent participation in the study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Patchett, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 2, 2021</study_first_submitted>
  <study_first_submitted_qc>December 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>David C. Patchett</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

